Why is ACADIA Pharmaceuticals stock climbing today?

ACADIA Pharmaceuticals' stock is experiencing a modest climb today, climbing 0.6% to reach $20.07. This comes after a tumultuous period where shares fell about a fifth of their value in just two sessions at the end of last month. The primary boost today is from RBC Capital, which has maintained its Outperform rating and $37 price target.

They argue that the company's established commercial franchise is trading at an overpriced level, with recent patent developments further decreasing the risks associated with Nuplazid's long-term revenue. This reassessment comes as the stock has been heavily oversold. On September 24, ACAD plunged after announcing that remlifanserin, its experimental drug for Alzheimer's disease psychosis, narrowly missed the primary endpoint in the Phase 2 RADIANT trial.

This led to a sharp selloff, followed by more declines the next day as analysts cut their price targets. Additionally, a securities law firm announced an investigation into the company's disclosures regarding the trial outcome. Despite these negative developments, most analysts covering ACAD still maintain Buy or equivalent ratings, with the consensus price target suggesting significant upside from today's price.

The combination of an institutional reaffirmation, deep oversold technicals, and a constructive market environment is driving the stock's recovery. However, with the stock still trading over 35% below its 52-week high of $30.96 and a legal investigation underway, sustained recovery will depend on the company's ability to provide a convincing outlook for the remlifanserin program and continued success with Nuplazid and Daybue.